Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q1 2025
Arcturus Therapeutics Holdings (ARCT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Arcturus Therapeutics Holdings (ARCT) reported revenue of $29.4M for the first quarter 2025 (Q1 2025), -23% from a year earlier and +29% from the quarter before. Operating margin was -57.3%, net loss $14.1M (47.9% of revenue).
Arcturus Therapeutics Holdings, Q1 2025: revenue $29.4M (-23% year over year), operating margin -57.3%, net loss $14.1M, operating cash flow −$35.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29.4M | +29% | -23% |
| Operating profit | −$16.8M | — | — |
| Net earnings | −$14.1M | — | — |
| Operating cash flow | −$35.1M | — | — |
What changed
Revenue was $29.4M in Q1 2025, down 23% year over year and up 29% from the previous quarter. Collaboration Revenue was the largest line at 87% of revenue. Collaboration Revenue lost $7.1M year over year (down 22%), 83% of the total change.
Operating costs exceeded revenue by $16.8M, an operating margin of -57.3%. Total costs fell 32% while revenue fell 23%. The quarter ended with a net loss of $14.1M, narrower than the previous quarter's $30.0M loss.
Operating cash flow was −$35.1M. Non-cash charges added back $801K of depreciation and amortization and $6.7M of share-based compensation. Working capital and other items used $28.5M. Capital expenditures of $137K exceeded it, leaving free cash flow of −$35.3M.
Questions
What was Arcturus Therapeutics Holdings' revenue in the first quarter 2025?
Arcturus Therapeutics Holdings (ARCT) reported revenue of $29.4M for the first quarter 2025 (Q1 2025), -23% from a year earlier and +29% from the quarter before.
Was Arcturus Therapeutics Holdings profitable in the first quarter 2025?
Operating loss was $16.8M (-57.3% of revenue) and net loss $14.1M.